David Deepu, Eapen Chundamannil E
Gastroenterology Department, Christian Medical College, Vellore, Tamil Nadu, India.
Hepatology Department, Christian Medical College, Vellore, Tamil Nadu, India.
J Clin Exp Hepatol. 2021 Mar-Apr;11(2):232-238. doi: 10.1016/j.jceh.2020.09.001. Epub 2020 Sep 3.
Of the currently available drugs tested to treat nonalcoholic fatty liver disease (NAFLD), the most efficacious drugs are pioglitazone (an insulin sensitizer) and vitamin E (an antioxidant). By targeting insulin resistance, the key pathogenic mechanism underlying metabolic syndrome and NAFLD, pioglitazone maybe the preferred drug to treat NAFLD. As we await the results of research trials into multiple new drugs to treat NAFLD, when should we use the currently available patients to treat NAFLD at the present time? To date, no drug has been approved by regulatory agency specifically to treat NAFLD. However, many drugs have been approved to treat other components of metabolic syndrome such as diabetes mellitus and dyslipidemia. Are we underutilizing the currently available drugs to treat NAFLD? Herein, we review the benefits and concerns of the use of these currently available drugs to treat NAFLD and suggest clinical scenarios, wherein the clinician should consider using these drugs.
在目前用于治疗非酒精性脂肪性肝病(NAFLD)的已测试药物中,最有效的药物是吡格列酮(一种胰岛素增敏剂)和维生素E(一种抗氧化剂)。通过针对胰岛素抵抗这一代谢综合征和NAFLD潜在的关键致病机制,吡格列酮可能是治疗NAFLD的首选药物。在我们等待多种治疗NAFLD新药的研究试验结果之际,目前应该何时使用现有药物来治疗NAFLD呢?迄今为止,尚无药物被监管机构专门批准用于治疗NAFLD。然而,许多药物已被批准用于治疗代谢综合征的其他组分,如糖尿病和血脂异常。我们是否未充分利用现有药物来治疗NAFLD呢?在此,我们回顾使用这些现有药物治疗NAFLD的益处和问题,并提出临床场景,临床医生在其中应考虑使用这些药物。